ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Stock Information for ProMIS Neurosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces First Quarter 2025 Financial Results
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
ProMIS Neurosciences Issues Letter to Shareholders
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.